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Our understanding of COVID-19, a disease caused by the novel coronavirus, SARS-CoV-2 
has been evolving rapidly since its outbreak in December 2019.1 Initially understood 
primarily as a respiratory disease, evidence suggests that the virus has an impact on other 
organs, including the kidney.2  
 
Pathogenesis of renal dysfunction in COVID-19 is likely multifactorial. ACE-2 receptors, the 
target for viral binding, are richly expressed in the renal tubular epithelium and podocytes.3 
Post-mortem examinations demonstrated that viral particles enter renal cells directly, leading 
to acute tubular necrosis and lymphocyte infiltration.4,5,6 In some cases, the virus triggers an 
overwhelming inflammatory response and cause a cytokine storm, which can cause renal 
tissue destruction.7 Additionally, the infection induces a hypercoagulable state,8 which can 
lead to small vessel thrombosis within the kidney.9  Besides the kidney-specific effects, 
systemic insults: dehydration, cardiac insufficiency, nephrotoxic medication and secondary 
sepsis all lead to renal underfilling and damage, further compounding the risk of acute kidney 
injury (AKI).3  
 
The exact incidence of AKI in COVID-19 patients is unclear due to extreme heterogeneity of 
reports. An early Wuhan study found no cases of AKI amongst over a hundred patients in the 
COVID-19 cohort, even when minimum pre-admission creatinine value was used as 
baseline.10  A large meta-analysis of nearly fifteen thousand patients from Europe, Asia and 
North America found that amongst 20 studies, rates of AKI ranged from 0.5% to 80.3%, with 
an average of 17%.  Two other meta-analyses have recently reported incidence of 10%11 and 
8.4%,12 respectively.  
 
It remains unknown whether risk of AKI in COVID-19 is elevated compared to the general 
population of hospital inpatients, estimated at about 20%. 13,14 The first study to make a direct 
comparison found that among patients hospitalised during the pandemic, those positive for 
SARS-Cov-2 had a greater risk of AKI (56.9%) than those with a negative result (37.2%); 
although baseline characteristics varied significantly between groups.15 Risk factors for AKI 
in COVID-19 patients seem to mirror those in the general population and include male sex, 
age, and presence of multiple comorbidities, including chronic kidney disease (CKD). 15–17  
 
AKI is a major cause of morbidity amongst COVID-19 patients. Although the majority of 
cases reported are classified as mild,17 a proportion of patients develop severe renal failure, 
with an estimated 5% requiring renal replacement therapy (RRT).17,18 Amongst survivors, as 
many as 65.2% never recover their baseline renal function after the episode.19,20  
 
AKI is also an independent predictor of mortality, even when adjusting for age, sex, disease 
severity and comorbidity burden.21 A meta-analysis estimated mortality rate of up to 52%; 
individual studies have cited rates between 7% and 100%.18 Prior to COVID-19, it was 
demonstrated that amongst hospitalised patients, development of AKI is associated with four-
fold increase in risk of death.13 AKI has been recognised as one of the major sources of 
preventable harm amongst inpatients, and has been a central focus of the national quality 
improvement framework in the last decade.22,23  
 
In one of the largest and most detailed UK studies on AKI in COVID-19, we will investigate 
a cohort of nearly two thousand patients with confirmed SARS-Cov-2 infection admitted to 
five acute hospitals in East London. A previous study on this cohort investigated the 
association between ethnicity and outcomes.24 This secondary analysis will focus on the 
incidence, risk factors and outcomes associated with AKI within this population. We will also 
examine follow-up data to investigate what proportion of COVID-19 patients who developed 




In line with other research, we expect that the rates of AKI amongst COVID-19 population 
will be high, and that the occurrence of AKI will be associated with poorer outcomes, 
including death, risk of ICU admission, and prolonged length of stay. 
 
 




To quantify the incidence of AKI in COVID-19 patients defined and determine risk factors 




To determine whether development of AKI in COVID-19 patients is associated with greater 
disease severity and worse outcomes. The primary outcome measure will be survival to 30-




- 30-day (primary) 
- 90-day 
Length of stay: 
- Duration in hospital 
- Duration on ICU 
Disease severity: 
- Admission to ITU 
- Need for organ support 
o Mechanical ventilation 
o Renal replacement therapy (RRT) 
Delayed recovery: 
- Discharge destination other than usual place of residence 
- Subsequent CKD diagnosis 
Composite outcome at day 90 (MAKE90) 
- Death within 90 days 






This secondary analysis will be carried out using the dataset of all patients included in the 
EthICAL study on ethnic disparities in COVID-19 outcomes.24 Details of data collection, 
data management and permissions are detailed in the EthICAL study documents. This cohort 
will include patients with a diagnosis of SARS-Cov-2 confirmed on PCR having an inpatient 
admission to any hospital within Barts Health Trust between 1st March and 13th May 2020. 
Follow-up data were available up to 1st December 2020. For this analysis, we will exclude 





Definition of key variables 
 
Acute Kidney Injury  
 
Acute Kidney Injury (AKI) is defined according to KDIGO criteria.25 The median creatinine 
value in the 7-365 days prior to admission will be used as baseline value. If no prior results 
are available, value will be imputed based on eGFR of 75ml/min/1.72m2 or the admission 
value, whichever is lower.  
 
Any rise in creatinine meeting criteria within the first 7 days of admission with be classified 
as AKI. Patients with AKI will be stratified into three groups based on severity: Stage 1 (peak 
creatinine 1.5-1.9 times baseline or ³ 26.5 µmol/L increase in 48h); Stage 2 (peak creatinine 
2.0-2.9 times baseline); and Stage 3 (peak creatinine 3 times baseline; ³ 26µmol/L increase to 
a value of 353.6 µmol/L or higher; or initiation of RRT).  
 
 
Table 1: KDIGO criteria for diagnosis of Acute Kidney Injury. 25 In this analysis, only biochemical criteria will be used as 
there is no data regarding urine outputs is available.  
 
Comorbidity and Hospital Frailty Risk score 
  
ICD-10 codes for all previous hospital encounters up to the current admission will be used to 
identify significant pre-admission co-morbidities. Cumulative Charlson comorbidity index26 
and Hospital Frailty Risk Score will be calculated using this information.27  
 
Body mass index (BMI) 
 
BMI will be calculated using weight and height taken at current or (if unavailable) 
penultimate admission episode.  
 
Chronic Kidney Disease (CKD)  
 
Cases of moderate-to-severe CKD will be defined as three or more months of eGFR of <60 








Up to date information regarding death was extracted on 1st December 2020. Death is defined 
as the presence of date of death or “patient died” as discharge destination in the EMR 




Data will be stored in Microsoft Excel (2019; version 16.34) and analysed using R software 





Baseline characteristics  
 
Baseline characteristics for patients with and without AKI will be summarised. AKI will be 
categorised by stage. Numbers (%), means (SD), and medians (IQR) will be provided 
separately for each group. The study groups will be compared using simple univariate tests. 
The difference between means of continuous variables will be analysed using ANOVA. For 
dichotomous data, Pearson Chi-square or Fisher exact test (if expected number <5) will be 
used.  
 
 no AKI AKI 






Age      
Sex      
Smoking      









     
MI      
CHF      
PVD      
CVD      
Dementia      
COPD      
Rheum 
disease 
     
Peptic ulcer      
Mild liver 
disease 
     
cDM      
DM      
Haemiplegia/ 
paraplegia 
     
Backg CKD      
ESRD      
Malignancy      
      
New CKD      
Death      
RRT      
Mechanical 
ventilation  
     
Sample Table 1: The assessment of risk factors and outcomes associated with AKI amongst COVID-19 patients 
 
Comparison of clinical outcomes 
 
Survival analyses will be carried out using Cox-proportional hazard models to determine the 
difference in 30-day mortality between the patients who develop AKI compared to patients 










Logistic and linear regression models will be used to assess the between-group differences 
for additional categorical and continuous secondary outcomes, respectively.  
 
Sensitivity analysis  
 
Secondary analysis of outcomes will be carried out for the following groups: 
• Late AKI – patients who only developed AKI after day 7 of admission 
• Persistent AKI – patients whose AKI persisted at day 7, including those who died 
before day 7 and all RRT patients  
• Recovered AKI – patients no longer meeting criteria for AKI at day 7 or at any later 
point during the admission  
• Relapsed AKI – patients recovered at day 7 who met criteria for AKI again at a later 
point during the admission 
 
Baseline creatinine values will be the same as in primary analysis.  
 
Survival will also be assessed using 90-day mortality.  
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